Currently, a clinical trial is underway to investigate the efficacy of an anti-LAG-3 monoclonal antibody in combination with anti-PD-1 for the treatment of castration-resistant PRAD (ClinicalTrials.gov identifier: NCT03365791). Here, LAG3 is linked to prostate adenocarcinoma.